Bio-Path Leukemia Combo Study Shows Positive Early Data
Zacks Investment Research | Apr 03, 2018 11:15PM ET
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced positive interim data from phase II study (BP1001-201) on its lead pipeline candidate — prexigebersen — in combination with low-dose cytarabine (“LDAC”) for the treatment of patients with acute myeloid leukemia (“AML”) who cannot or choose not to be treated with more intensive chemotherapy.
The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy compared with LDAC alone. Shares of the company rose by almost 25% following the news.
The combination therapy demonstrated early anti-leukemic activity in nearly 50% of evaluable AML patients. Out of the 17 evaluable patients, four patients achieved complete remission and four experienced stable disease to date in this study. In total, 47% of patients achieved some form of response from the combo treatment.
The combination was also well tolerated in the study.
Shares of the company have underperformed the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.